Status:
UNKNOWN
A Single-center Clinical Study to Evaluate the Safety and Efficacy of Autologous Bone Marrow-derived DCs(CellgramDC-WT1) and Immune Checkpoint Inhibitors in Patients With Metastatic Pancreatic Cancer Who Have Failed First-line or More Standard Chemotherapy
Lead Sponsor:
Soonchunhyang University Hospital
Conditions:
Pancreas Cancer
Eligibility:
All Genders
19-80 years
Phase:
PHASE1
PHASE2
Brief Summary
To evaluate the safety and effectiveness of immune cell therapy using autologous bone marrow-derived dendritic cells and immune checkpoint inhibitors in patients with metastatic pancreatic cancer who ...
Detailed Description
After a test subject agrees in writing to participate in a clinical study, if he or she is determined to fit the selection criteria and does not meet the exclusion criteria through a screening process...
Eligibility Criteria
Inclusion
- Patients histologically confirmed to have pancreatic cancer and diagnosed as recurrent or metastatic
- Patients whose disease was confirmed to have progressed according to RECIST v1.1 after 1st or more standard anticancer treatments
- Patients satisfying systemic performance status ECOG 0-2
- Patients who have not undergone surgery, radiation therapy, or immunotherapy within 4 weeks and have recovered from side effects (However, tissue collection procedures that do not affect the test subject's condition are permitted at the discretion of the researcher.)
- Patients who voluntarily agreed in writing to participate in this clinical study
Exclusion
- Patients with malignant tumors other than non-melanoma skin cancer in the past 3 years
- Patients who have previously received anti-tumor immunotherapy (anti-PD1, anti-PDL-1, or CTLA4 inhibitor, etc.) or participated in clinical studies related to immunotherapy or cell therapy
- Patients with active autoimmune disease requiring systemic immunosuppressive treatment
- Patients with a history of organ or hematopoietic stem cell transplantation
- Patients with acute or chronic infection requiring systemic treatment
- Other cases where the test manager determines that it is not suitable for clinical research
Key Trial Info
Start Date :
March 1 2024
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 31 2025
Estimated Enrollment :
10 Patients enrolled
Trial Details
Trial ID
NCT06172634
Start Date
March 1 2024
End Date
December 31 2025
Last Update
December 15 2023
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.